Due to advances in understanding of melanoma biology, immunotherapy and target therapy, alone or in combination, have shown promising results in the treatment of advanced melanoma.13 Selection of most appropriate treatment depends on multiple factors, including patient's performance status and preferences, site (ie, brain) and extension of metastases, and the presence of specific genetic mutations (BRAF, n-RAS, and c-KIT). This evidence concerns the gene KIT and melanoma.